Drug Profile
Research programme: viral infection therapies - Quigley Pharma
Alternative Names: QR-435; QR-439; QR-441; QR-444; QR-446Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Quigley Pharma
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections; Influenza A virus infections; Severe acute respiratory syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in United Kingdom (Intranasal, Spray)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in USA (Intranasal, Spray)